Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched study DIAB-A22-1 to explore the therapeutic potential of its DehydraTECH-processed CBD for diabetes. The research involves 32 male Zucker rats over 56 days to assess weight gain, blood glucose, cholesterol, and triglyceride levels. Lexaria's technology has previously shown promise in hypertension. The diabetes market is significant, with global device and drug markets estimated at $26.7 billion and $63.1 billion, respectively. Results from the study are expected in early January 2023.
- Launch of study DIAB-A22-1 to investigate CBD's effects on diabetes.
- Previous success of DehydraTECH-CBD in hypertension studies.
- Significant market opportunity in diabetes treatment, valued at $89.8 billion combined for devices and drugs.
- None.
KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DIAB-A22-1 is expected to begin on schedule today. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol ("CBD") may potentially have therapeutic utility against diabetes.
Lexaria has previously evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies. There are strong connections between heart disease, hypertension, and diabetes: hypertension is twice as frequent in diabetics and hypertensive patients are at greater risk of developing diabetes.
Diabetes prevents the body from making enough insulin, resulting in abnormal blood sugar levels. It is the 7th largest cause of death in the US and there is currently no cure. Investigation of CBD related to diabetes is in early stages, though there are some areas of ongoing investigation. CBD has shown some ability to reduce the incidence of diabetes in mice.
ABOUT THE STUDY
Study DIAB-A22-1 is a dose-ranging, 56-day program in a total of 32 male Zucker rats, 24 obese and 8 lean, that will compare weight gain, blood glucose, cholesterol and trigyceride levels in animals that receive DehydraTECH-CBD to those that do not. The first 28 days of the study is a baseline validation and monitoring phase and the second 28 days of the study will include the daily DehydraTECH-CBD dosing and treatment phase. Blood will be drawn for analysis on days 0, 13, and 27 during the validation phase, and on days 7, 14 and 28 during the treatment phase.
Study DIAB-A22-1 will be undertaken by a leading, third-party testing laboratory located in Canada. The laboratory work is expected to complete in early January 2023 with data and reporting to follow thereafter. Lexaria will provide further updates and any relevant material findings in due course from this study as they become available.
ABOUT THE DIABETES MARKET OPPORTUNITY
Diabetes is a disease whereby the body does not produce sufficient insulin, leading to higher than normal levels of sugars in the blood. Risks of kidney disease, vision loss, heart and cardiovascular disease and more are greatly enhanced by sufferers of diabetes. Because diabetes is often closely connected to obesity, it is a chronic and growing problem around much of the world.
People with type-2 diabetes can often control the disease through lifestyle changes and/or taking certain diabetes medications, whereas those with type-1 diabetes are required to add insulin to their body through syringes, insulin pumps, or other similar devices. Thus the treatment of diabetes includes devices, drugs, and lifestyle alteration. The global diabetes devices market is estimated at
ABOUT LEXARIA BIOSCIENCE CORP.
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View source version on accesswire.com:
https://www.accesswire.com/724465/Lexaria-Starts-Study-Evaluating-the-Effect-of-DehydraTECH-CBD-on-Diabetes
FAQ
What is study DIAB-A22-1 by Lexaria?
When will results from the diabetes study DIAB-A22-1 be available?
What are the market opportunities for diabetes treatment?
What is DehydraTECH technology?
What is the significance of Lexaria's diabetes study?
